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Aim To assess the association between first reactions to cannabis and the risk of cannabis 
dependence. 
Design A cross-sectional population-based assessment in 2007. 
Setting A campus in a French region (Champagne-Ardennes). 
Participants A total of 1472 participants aged 18-21 years who reported at least one lifetime 
cannabis consumption, out of 3.056 students who were initially screened (the SAGE study).  
Measurements Positive and negative effects of first cannabis consumptions, present cannabis 
dependence and related risk factors were assessed through questionnaires. 
Findings The effects of first cannabis consumptions were associated, in a dose dependent-
manner, with cannabis dependence at age 18-21 years, both according to the transversal 
approach of the SAGE study and to the prospective cohort of the Christchurch Health and 
Development Study (CHDS) assessed at the age of 25 years. Participants of the SAGE study 
who reported 5 positive effects to their first cannabis consumptions had odds of lifetime 
cannabis dependence that were 28.7 (95% CI: 14.6-56.5) higher than those who reported no 
positive effects. This association remains significant after controlling for potentially 
confounding factors, including individual and familial variables.  
Conclusions This study suggests an association between positive reactions to first cannabis 
uses and risk of lifetime cannabis dependence, this variable having a central role among, and 
through, other risk factors. 
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Introduction 
             
Several childhood and adolescent predictors of substance abuse have been described. 
Male gender [1, 2], drug availability [2, 3], peers use of cannabis [2], delinquency and 
conduct disorder [3, 4], a familial or personal history of other substance use [2, 4-8] are 
among the most consistent predictive factors of cannabis dependence. 
More recently, some studies focused on the role of the subjective reactions 
encountered during early substance uses on later dependence [7, 9, 10].  
For example, the number of drinks required to observe a behavioural effect during the 
five first consumption of alcohol  is associated with a higher risk of alcohol dependence [11, 
12]. Similarly, feeling relaxed during the first cigarette consumption is a strong predictor of 
later nicotine dependence [13].  
Cannabis consumers usually report positive expectancies of their consumption [14]. A 
prospective study in New-Zealand by Fergusson et al. more precisely showed that the 
subjective reactions to cannabis use prior to the age of 16 years were associated with an 
increased risk of cannabis dependence at the age of 21 years [15]. Rates of cannabis 
dependence increased in a dose dependent manner with increasing reports of positiveresponse 
to early cannabis use, this association remaining significant after controlling for several 
confounding factors.  
However, these findings were not verified after the initial 5 years follow-up, and they 
were not replicated in a sample with a different socio-cultural background, e.g. they were not 
checked for cultural specificities.  
The present study examined the relationship between the effects of first cannabis use 
and the risk of cannabis dependence in adulthood. The aims of this study were twofold: (1) 
testing the reliability of first reactions to cannabis as a risk factor for later dependence, 
extending the follow-up from 5 to 10 years, and (2) examining whether the association 
between effects of first cannabis use and the risk of cannabis dependence in adulthood found 





The Susceptibility Addiction Gene Environment (SAGE) study aimed to assess 
addictions and psychiatric disorders with self-report questionnaires in a large cohort of young 
adults. All 3895 college students of the French region “Champagne Ardennes” were eligible. 
Among them, 3.056 (1834 males and 1224 females; mean age 20.42 years, s.d. 1.4) were 
enrolled on their campus during a single day and completed an intake assessment. There is no 
demographic and clinical information available on the subjects who refused the interview or 
were not present on the day of interview. The studied subsample was limited here on 1472 
subjects (48.23%) who ever smoked cannabis in their lifetime. For these subjects, less than 
5% of the data were lacking. Thus, all were included in the analysis. 
            The validity of the questionnaire has been assessed in a preliminary study, conducted 
in another French campus. Participation was proposed (30% refusal rate) for students getting 
in the library of the university during a specific time range. This pilot study included 69 
students (70.9% of females), mean age 21.39 years (sd:1.34), who were initially assessed by 
the auto-questionnaire of the SAGE study and then by a trained psychologist, blind for the 
answers initially given, using a face-to-face semi-structured interview, the Diagnostic 
Interview for Genetic Studies (DIGS).  
  
Measures 
Subjective reactions to the first cannabis uses 
  
Subjective reactions to first cannabis uses were assessed with questions relating to 
their subjective reactions on the first occasion they used cannabis, covering both positive 
(getting really high, feeling happy, feeling relaxed, doing silly things, laughing a lot) and 
negative (feeling ill or dizzy, feeling frightened, passing out) experiences, described in 
Fergusson et al. [15] and translated into French.  
  
Cannabis dependence 
Lifetime cannabis dependence was assessed according to DSM-IV criteria [16], using 
a self-report questionnaire derived from the DIGS [17, 18]. This questionnaire comprises 10 
questions covering the 7 items corresponding to DSM-IV criteria for substance dependence. 
Participants received a diagnosis of cannabis dependence if they met 3 or more of the 7 DSM-
IV criteria. 
In the preliminary sample, the level of agreement between the questionnaire and the 
semi-structured interviewfor the diagnosis of lifetime cannabis dependence was evaluated as 
good, as the number of symptoms of lifetime cannabis dependence from the auto- versus the 
hetero-questionnaire were highly correlated (r=0.928, df=70; p<0.001), and the kappa value 
for the diagnosis of cannabis dependence was very good (Kappa=0.80, var[Kappa]=0.013). 
  
Confounding factors 
Several variables could have a confounding influence either on the first reactions to 
cannabis, or to the relationship between first reactions to cannabis and cannabis dependence. 
The following variables were selected either on the basis of their previous use as potential 
confounding factors in the literature, or because they were associated with first reaction to 
cannabis or to cannabis dependence in our sample. 
  
1.Demographic and socioeconomic background characteristics of the participant and 
of the family 
The assessment of the family structure was based on the question “Do you live …?” 
with 11 possible response alternatives, including living with two biological parents, living 
with mother alone, with father alone, with mother and another male, with father and another 
female, with another family member, with an adoption family, alone, in couple, with other 
youths, and in an institution. Completed years of education (0-7 years; 7-11 years; 11-14 
years; 14-18 and >18 years), and current occupation (active; unemployed; retired; disabled or 
deceased) were also assessed for each parent. 
  
2.Adolescent conduct problems 
History of conduct disorder was assessed using a self-report questionnaire derived 
from the DIGS [17, 18]. Participants received a diagnosis of conduct disorder if they met 3 or 
more of the 15 DSM-IV criteria. In the preliminary sample, the questionnaire and the semi-
structured interview both detected the same 8 subjects with past history of conduct disorder 
(Kappa=1),. 
  
3.Past attentional deficit / hyperactivity (ADH) symptomatology  
The extent of past ADH problems was assessed using a French validated shortened 
version of the Wender Utah Rating Scale (WURS) [19].  
  
4.                 Current depression and lifetime suicide attempts 
Depression was assessed using the Adolescent Depression Rating Scale (ADRS) [20]. 
A score of 4 or above has been shown to differentiate patients suffering with major 
depressive disorder from those without [20]. 
Lifetime suicide attempt was assessed using a single question: Have you ever made a 
suicide attempt? Participants who reported suicide attempt were asked to report age at first 
suicide attempt. In the preliminary sample, the 8 suicidal attempts reported on the auto-
questionnaire were confirmed on the basis of the clinical interview (Kappa=1), as well as the 
age at onset of the first suicide attempt (Kappa=1). 
  
5.Impulsivity 
In the SAGE study, impulsivity was evaluated with the self report Plutchik Impulsivity 
Scale (IS), a 15 items self-rating scale [21]. 
  
6.Past and current substance use 
Alcohol related behaviours of the participant were assessed using a French version of 
the Alcohol Use Disorder Identification Test (AUDIT), a 10-item questionnaire [22].  
            Nicotine dependency was assessed using Fagerström Test for Nicotine Dependence 
(FTND) [23].  
Exposure to other drugs was assessed through 12 items based on the question “Have 
you ever used...?” including cocaine, amphetamine, unprescribed tranquilizers, opiates/heroin, 
PCP, LSD, hallucinogenic drug, solvents, ecstasy, GHB, sniffed drug, injected drug. 
Participants who ever tried one of these drugs were classified as exposed. 
Age at first cannabis consumptions was assessed with a single question “How old were 
you when you first tried marijuana or hashish?”. In the preliminary sample, the age of 
initiation proposed by the subject was very close to the one according to the clinician (15.98 
years old for the clinician, 15.96 for subjective rating, p>0.90), the two ages being highly 
correlated (r=0.976, df=30, p<0.001). 
  
7.Sexual abuse 
Participants fulfilled a questionnaire assessing the exposure to sexual abuse involving 
attempted or completed unwanted sexual intercourse, as well as the age at first unwanted 
sexual intercourse. In the present analysis, we classified participants in four categories, (i) 
participants reporting no unwanted sexual intercourse; (ii) participants reporting sexual abuse 
not involving attempted or completed intercourse; (iii) participants reporting unwanted 
attempted sexual intercourse; (iv) participants reporting unwanted sexual intercourse. In the 
pilot sample, the three subjects (4.3%) reporting sexual abuse did so in both the auto-
questionnaire and the clinical interview (Kappa=1), these events occurring during childhood 
(between 4 and 8 years old). 
  
8.Family and peers substance use and violence 
Participants rated paternal and maternal drinking problems with F-MAST and M-
MAST auto-questionnaires [24]. F-MAST and M-MAST are adapted versions of the MAST, 
the Michigan Alcoholism Screening Test  ADDIN EN.CITE 
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urls></urls></record></Cite></EndNote>[25], and screen alcohol abuse symptoms in both 
parents according to their child, with good reliability and validity [24]. 
Parental smoking was assessed with two questions, evaluating past regular 
consumption and current daily smoking for each parent.We distinguished 3 levels: (i) none of 
the parents has been a regular smoker; (ii) at least one parent was a regular smoker but no one 
is a current daily smoker; (iii) at least one parent is a current daily smoker. 
  
Parental cannabis consumption was assessed with three questions, evaluating past 
exposure, past regular consumption and current daily consumption of cannabis for each 
parent. We distinguished the same 3 levels of consumption: (i) none of the parents smoked 
cannabis; (ii) at least one parent smoked cannabis but no one was a regular cannabis smoker; 
(iii) at least one was a regular cannabis smoker. In the pilot sample, this three classes 
distribution was virtually identical according to the self-questionnaire and the clinical 
interview. 
  
 CHDS sample 
  
Participants in the second sample were drawn from the Christchurch Health and 
Development Study (CHDS) cohort. The CHDS is a birth cohort of 1265 children (635 males 
and 630 females) born in mid-1977 and assessed at birth, 4 months, 1 year, and annually to the 
age of 16 years, and again at the ages of 18, 21, and 25 years. Study informations were 
collected  by trained interviewers, via face-to-face or telephone interviews (in cases in which 
respondents were overseas). Details about the sample are reported elsewhere [26, 27].  
Data on early reactions to cannabis and the risk of later dependence at age 21 in the 
CHDS, as well as confounding factors, have been previously reported [15], but were extended 
herein to the risk of dependence at age 25. The confounding factors included: the frequency of 
cannabis use (for 14- to 16-year-olds), gender, socioeconomic status, childhood sexual abuse, 
parental change and interparental violence, parental attachment, adolescent tobacco and 
alcohol use, adolescent conduct problems, deviant peer affiliations, and novelty-seeking 




We assessed the significance of the association between positive and negative 
symptoms counts and the risk of lifetime cannabis dependence in the French sample using 
hierarchical binary logistic regression. The strength of the association was estimated with 
unadjusted and adjusted odds ratio. The dependent variable was “cannabis dependence”, and 
the number of positive symptoms and number of negative symptoms were treated as 
continuous predictors of cannabis dependence.  
To estimate the unadjusted odds ratios, the number of positive reactions at first 
cannabis consumptions was the only covariate. To estimate the adjusted odds ratios, all 
confounding variables were used. This method was repeated for the number of negative 
reactions.  
Study protocols for the SAGE study were approved by the ethical review boards from 
INSERM and CNIL (# 907003), and for the CHDS by the Canterbury Ethics Committee. 
Written informed consent was obtained from all participants. None of the subjects was paid 




The demographic and clinical characteristics of the participants to the SAGE study are 
shown in Table 1. The rate of dependence at the age of interview was 17.7%. Parental 
cannabis consumption was higher in cannabis dependent participants than in non dependent 
cannabis users. Indeed, 14.9% had at least one parent exposed to cannabis and 32.4% reported 
that one parent has been a regular user, versus 2.8% and 22.9% in the non dependent cannabis 
user group respectively (p<0.001). Cannabis dependent participants were less likely to live 
with their two biological parents that non dependent users (48.3% versus 58.9%, p<0.001). 
Father and mother completed years of education, current occupation and smoking statues 
were not different betweenthe two groups. 
Cannabis dependence was found associated to positive experiences with odds ratio 
over 2 (Table 2). Furthermore, an increasing number of positive reactions was associated with 
increasing rates of cannabis dependence (Table 3). Accordingly, the odds ratios of the number 
of reported positive reactions are ranging from 1.9 (95% CI: 1.7-2.2) for participants who 
reported one positive reaction, to 28.7 (95% CI: 14.6-56.5) for participants who reported five 
positive reactions (p<0.001). Increasing negative reactions to first cannabis use were 
unrelated to later cannabis dependence.  
To estimate the adjusted odds ratios, all confounding variables were used in a first 
block, whereas the variable assessing the number of positive reactions to first cannabis use 
was included in a second block. The first level (no positive reaction) was defined as the 
reference (Table 3). This method was repeated for the number of negative reactions. Adjusted 
odds ratio between cannabis dependence and positive reactions are ranging from 1.6 (95% CI: 
1.3-1.9), for participants who reported one positive reaction, to 11.0 (95% CI: 4.5-26.4) for 
participants who reported five positive reactions (p<0.001). Again, increasing negative 
reactions to first cannabis use were not related to later cannabis dependence.   
Since some of the events controlled for could have occurred after the onset of cannabis 
use, we reanalysed our data taking into account as covariates only the behaviors or event that 
occurs previous to the first cannabis consumption of a given participant. We found no 
significant differences with the previous results (data not shown). 
We also wanted to test whether the mean of positive effects of cannabis consumption depends 
on the number of joints consumed during the last month ( 1 to 2 joints;  3 to 9; more that 10 
joints), excluding both current abstinent and dependent subjects. On this subsample of 167 
subjects, we found no significant differences between groups in the number of positive effects 
encountered during early consumption according to an ANOVA (F=0.80; p=0.92). 
  
We then examined participant of the CHDS cohort, who have been followed up to 
adulthood, to assess the temporal stability of the initial finding. We tested whether the number 
of positive and negative reactions to early cannabis, reported by the age of 16 years, was still 
associated with longer term risk of cannabis dependence, evaluated at the age of 25 years. 
Table 4 reports data for the 198 participants of the CHDS who had used cannabis at 
least once by the age of 16 years. For the positive symptoms scale, an increase in the number 
of positive reactions was associated with increasing rates of cannabis dependence by the age 
of 25 years (p<0.001), with those who reported 5 positive symptoms having odds of cannabis 
dependence that were estimated to be 8.0 (95% CI: 2.5-25.3) times greater than for those who 
reported no positive symptoms. Increasing negative reactions to early cannabis use were not 
related to later cannabis dependence. The associations between early reactions and later 
cannabis dependence were then adjusted for confounding factors that may be correlated with 
both early reactions and later dependence. After adjustment,the number of positive symptoms 
was still significantly associated with the risk of dependence (p = 0.04). The adjusted odds 
ratio for those reporting five positive symptoms was 4.0 (95% CI: 1.06-14.9). The number of 
negative symptoms remained unrelated to risk of cannabis dependence after adjustment for 
confounding variables.  
             
Discussion 
Positive experiences to early cannabis consumptions are important risk factors for later 
cannabis dependence in the present study. We were indeed able to confirm this hypothesis 
with a 9-year follow-up of the very first study which showed this effect (4). We further 
reinforced this link in a much larger sample of more than 3000 students. Having numerous 
positive reactions during the first consumptions of cannabis might therefore constitute a 
significant risk factor for later cannabis dependence. The fact that such a link was observed 
(1) using different measures of cannabis dependence (clinical interview in the CHDS cohort 
and auto-questionnaire in the SAGE protocol), (2) using two different methodologies 
(prospective versus transversal approaches), and (3) in two different populations (New 
Zealand for the CHDS study and France for the SAGE study) increase the chances that this 
result is not a false positive. 
Patterns of cannabis consumption are very different between France and New Zealand. 
For example, cannabis is consumed without mixing it with tobacco in New Zealand [28], 
whereas in France the typical consumption involves mixing it [29]. The fact that we could 
replicate the findings by Fergusson et al., despite these differences, confirms that the 
association between cannabis effects at first consumptions and the risk of later dependence is 
probably not due to confounding factors associated with a specific pattern of consumption or 
to a cultural artefact. 
We choose to consider positive versus negative effects rather that subjective effects as whole 
because i) our first aim was to replicate the findings by Fergusson et al. [15], ii)  the number 
of positive effects is  negatively correlated with the number of negative effects in our sample, 
although with a non-significant trend (Pearson r=-0,050; p=0.073), and iii) a factor analysis of 
the subjective effects of cannabis consumption (based on another scale) showed the existence 
of two factors, encompassing positive and negative effects respectively [30]. 
The associations reported between early positive reactions to cannabis and later risks 
of cannabis dependence by age 25 in the CHDS cohort are substantially weaker than the 
associations reported in the original analysis which examined risks of dependence only up to 
age 21 [15]. Closer examination of the data suggested that the attenuation of association with 
increasing length of follow-up was largely due to the fact that amongst those who reported 5 
positive symptoms to early cannabis use, all those who subsequently developed cannabis 
dependence had done so by age 21, whereas a small number of those reporting no positive 
symptoms had gone on to develop cannabis dependence after age 21. 
  
Several limitations should be raised. 
 First, the SAGE sample was assessed using a cross-sectional design, which increases 
the risk of misclassification of early cannabis effects because of retrospective assessment. 
Subjects who were cannabis dependent at the time of interview could have been more likely 
to report effects because they used cannabis on more occasions, and therefore more likely to 
remember subjective effects than subjects who were not cannabis dependent. However, the 
main finding of our study was initially described in the CHDS sample, a birth cohort using a 
prospective design in which reactions to cannabis were assessed prior to the development of 
cannabis dependence. Furthermore, the similarity of the variation of odds-ratios (Tables 3 and 
4) between number of positive effects and cannabis dependence between the two samples 
(SAGE and CHDS) is not in favour of an important bias. Another reinforcing point is that the 
impact of initial positive effects was specifically involved, whereas negative effects were not. 
A second limitation of the study is that the assessment was based on self-assessments 
rather than on clinical interview. However, our preliminary validation study showed good 
tovery good agreement between self-assessment and clinical interview, therefore reducing the 
risk of misclassification.  
A third possible limitation is that there is yet no laboratory validation study of the 
scale we use to measure the subjective effects of cannabis. While cannabis injection is 
associated with euphoria, as measured with a visual analogic scale in healthy subjects [31], 
further studies should aim to assess the sensitivity and specificity of a more reliable scale 
against a cannabis challenge test, focusing on the subjective effects encountered after a 
cannabis administration..  
A fourth limitation is the limited generalizability of the SAGE cohort, which assessed 
only current students, thus not representative of the general population. However, the 
replication in the CHDS cohort suggests that the effects of early cannabisconsumption are 
likely to be the same in different populations.  
  
The feasibility of a population-based specific screening of individuals having 
numerous positive reactions during the first consumptions of cannabis, as well as the cost-
effectiveness of a specific prevention remains largely unknown. Moreover, a public health 
policy based on a “high-risk” population  may lead to a false sense of security in the rest of 
the population, whereas the risk of cannabis dependence exists even in these groups. 
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Table 1: Demographic and clinical characteristics of 1472 college students who smoked 







Lifetime cannabis  
dependent subjects 
N=261 
p value a 
  N % within   N % within   
Male gender   759 62.7   196 75.1 <0.001 
Lifetime suicide attempt 67 5.6   18 6.9 0.394 
Lifetime sexual abuse           <0.001 
No 1176 97.0   248 94.7   
Yes, no AI 4 0.3   7 2.7   
Yes, AI 20 1.7   2 0.8   
Yes, intercourse 12 1.0   5 1.9   
Conduct disorder 167 13.8   93 35.5 <0.001 
Ever used drugs 210 19.5   149 59.4 <0.001 
  Mean SD   Mean SD   
Age (years) 20.4 1.4   20.7 1.5 <0.01 
Age at first cannabis 
consumption (years) 
16.1 1.7   14.9 1.5 <0.001 
AUDIT score 4.7 4.2   8.0 4.9 <0.001 
Fagerström score 1.1 2.4   3.1 3.6 <0.001 
Wurst ADH score  19.0 12.6   24.7 14.7 <0.001 
Plutchik impulsivity score  31.2 4.9   33.4 5.1 <0.001 
ADRS depression score  1.4 1.8   1.8 2.0 <0.01 
              
SD, standard deviation; AUDIT, Alcohol Use Disorder Identification Test; ADH, attentional 
deficit / hyperactivity; ADRS, Adolescent Depression Rating Scale: AI, Attempted 
intercourse;  
a p value showing a significance is indicated in bold  
  
Table 2: Rate of lifetime cannabis dependence by subjective response to early cannabis 
consumption in 1472 college students who smoked cannabis at least once during their lifetime 
 














    N   %       
Positive experiences           
Getting really high               
Yes   356   34.8   3.5 (2.6-4.7) <0.001 
No   984   13.0   1.0   
Feeling happy               
Yes   780   23.5   2.2 (1.6-3.0) <0.001 
No   555   11.9   1.0   
Feeling relaxed               
Yes   952   22.3   2.7 (1.8-3.9) <0.001 
No   398   9.5   1.0   
Doing silly things               
Yes   201   38.3   3.4 (2.5-4.8) <0.001 
No   1125   15.1   1.0   
Laughing a lot               
Yes   861   24.9   3.6 (2.5-5.2) <0.001 
No   496   8.3   1.0   
Negative experiences           
Feeling ill or dizzy               
Yes   227   16.7   0.8 (0.6-1.2) 0.458 
No   1104   18.8   1.0   
Feeling frightened               
Yes   97   24.7   1.5 (0.9-2.4) 0.090 
No   1229   17.8   1.0   
Passing out               
Yes   24   16.7   0.8 (0.3-2.5) 0.814 
No   1299   18.6   1.0   
                
  
a p value showing a significance is indicated in bold 
Table 3: Rate of lifetime cannabis dependence by the number of positive and negative 
symptoms at early consumption in 1472 college students who smoked cannabis at least once 
during their lifetime 
  
Measure   












    N   %       
N° of positive 
symptoms 
experiences 
            
  
0   177   2.9   1.0 1.0 
1   231   7.9   1.9 (1.7-2.2) 1.6 (1.3-1.9) 
2   238   13.9   3.8 (2.9-5.0) 2.6 (1.8-3.7) 
3   377   19.4   7.4 (5.0-11.2) 4.2 (2.5-7.1) 
4   221   35.3   14.7 (8.5-25.2) 6.9 (3.4-13.7) 
5   53   56.6   28.7 (14.6-56.5) 11.0 (4.5-26.4) 
            p<0.001 p<0.001 




            
  
0   1058   18.2   1.0 1.0 
1   188   19.7   1.0 (0.8-1.3) 0.9(0.6-1.3) 
2+   68   17.6   1.0 (0.6-1.7) 0.8 (0.4-1.6) 
            p=0.86 p=0.59 
a Odds ratio estimates derived from a linear logistic model in which the log odds of 
dependence was regressed on the continuous symptom score 
b Odds ratios after adjustment for confounding factors, including: sex; family structure; father 
completed years of education; father current occupation; mother completed years of 
education; mother current occupation; past conduct disorder; child attention deficit 
.hyperactivity symptoms; ADRS depression score; lifetime suicide attempt; impulsivity; 
AUDIT score; Fagerström score; exposure to other drugs; age at first cannabis consumption; 
sexual abuse; father and mother MAST scores; parental cigarette smoking, and parental 
cannabis consumption. 
Table 4: Rate of lifetime cannabis dependence at age 16-25 years by the number of positive 
and negative symptoms at age 14-16 years in the CHDS sample 
  
Measure   









OR (95%CI) a 
Adjusted 
OR (95%IC) a, b 
    N   %       
N° of positive effects           
0   26   15.4   1.0 1.0 
1   14   0.0   1.5 (1.2 – 1.9) 1.3 (1.01 - 1.7) 
2   33   21.2   2.3 (1.4 – 3.6) 1.7 (1.02 - 2.9) 
3   42   26.2   3.5 (1.7 – 7.0) 2.3 (1.03 - 5.1) 
4   53   37.7   5.3 ( 2.1 – 13.3) 3.0 (1.05 - 8.7) 
5   30   46.7   8.0 (2.5 – 25.3) 4.0 (1.06 - 14.9) 
            p<.001 p=0.04 
N° of negative effects          
0   141   26.2   1.0 1.0 
1   35   37.1   1.1 (0.7 – 1.8) 0.94 ( 0.5 - 1.7) 
2+   22   27.3   1.3 ( 0.5 – 3.2) 0.88 (0.3 – 2.7) 
            p=.54 p=.83 
  
a Odds ratio estimates derived from a linear logistic model in which the log odds of 
dependence was regressed on the continuous symptom score 
b Odds ratios after adjustment for confounding factors, including:: frequency of cannabis use 
(14-16 years); sex; socioeconomic status; childhood sexual abuse (< 16 years); changes of 
parents (0-15 years); inter-parental violence (0-16 years); parental attachment (15 years); 
frequency of cigarette smoking (15 years); frequency of alcohol use (15 years); conduct 
problems (15 years); deviant peer affiliations (15 years); novelty seeking (16 years). 
  
 
